Efficacy of pegylated interferon α monotherapy in inactive chronic hepatitis B virus carriers

doi:10.19871/j.cnki.xfcrbzz.2023.02.011

Abstract

Abstract: Objective To evaluate the the HBsAg loss and serological conversion rate of pegylated interferon alpha (Peg-IFN-α) treatment in inactive hepatitis B surface antigen carrier(IHC). Method 58 IHC patients, who admitted to the department of liver disease in Luohu People's Hospital from January 2019 to December 2021, were divided into treatment group (35 cases) and control group (23 cases) according to the patient's willings. Treatment groups were subcutaneously administered with Peg-IFN-α-2a or Peg-IFN-α-2b for 180μg/week for 48 weeks. The control group was not given any antiviral treatment. HBsAg clearance and serological conversion rate were compared between the two groups, Logistic regression was used to analyze the factors affecting HBsAg loss in Peg-IFN-α treatment with IHC. Result The mean baseline HBsAg levels were 172.99U/ml and 106.22U/ml in the treatment and control groups, respectively. For 48 weeks of treatment, loss of HBsAg was obtained in 40% (14/35) of IHC in the treatment group, HBsAg seroconversion in 14.3% (5/35) of IHC, and HBsAg loss and serological conversion were not observed in the control group. The HBsAg loss and HBsAg seroconversion rates were significantly higher than those in the control group (P<0.05).Baseline HBsAg levels and the magnitude of HBsAg decrease at 12 weeks and 24 weeks were independent factors affecting the occurrence of HBsAg clearance in Peg-IFN-αtreated IHC. No serious adverse events occurred during treatment. Conclusion Peg-IFN-α improves the HBsAg loss and serological conversion rate of IHC and the treatment is safe and effective.

Key words: Inactive HBsAg carrier, Chronic hepatitis B, Pegylated interferonα, Clinical cure

CLC Number:

R512.6

Luo Jie, Du Zhan, Dou Xiaowen, Li Jian, Chen Mingfa, Li Manni, Yin Yanyao. Efficacy of pegylated interferon α monotherapy in inactive chronic hepatitis B virus carriers[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(2): 53-57.

References

[1] CHU CM, LIAW YF.Spontaneous relapse of hepatitis in inactive HBsAg carriers[J]. Hepatol Int, 2007, 1(2):311-315.
[2] CHEN JD, YANG HI, ILOEJE UH, et al.Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death[J]. Gastroenterology, 2010, 138(5):1747-1754.
[3] MOUCARI R, KOREVAAR A, LADA O, et al.High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study[J]. J Hepatol, 2009, 50(6):1084-1092.
[4] YUEN MF, WONG DKH, FUNG J, et al.HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of heaptocellular carcinoma[J]. Gastroenterology, 2008, 135(4):1192-1199.
[5] CHU CM,LIAW YF.HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up[J]. Hepatology, 2007, 45(5):1187-1192.
[6] 丁霞, 廖桂婵, 夏牧晔, 等. 探讨长期核苷(酸)类药物治疗慢性乙型肝炎患者停药后复发的影响因素[J/CD]. 新发传染病电子杂志, 2019, 4(1):52-55.
[7] LI MH, XIE Y, ZHANG L, et al.Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a[J]. World J Hepatol, 2016, 8(15): 637-643.
[8] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2668.
[9] 任婷婷, 徐光华, 李春霞. 非活动性HBsAg携带状态的自然转归[J]. 肝脏, 2014, 19(1):71-73.
[10] SONG AX, LIN X, CHEN XY.Functional cure for chronic hepatitis B: accessibility, durability, and prognosis[J]. Virol J, 2021, 18(1):114.
[11] WU FP, YANG Y, LI M, et al.Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤1500U/ml: an observational study[J]. World J Gastroenterol, 2020, 26(13): 1525-1539.
[12] HU P, SHANG J, ZHANG W, et al.HBsAg loss with Peginterferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study[J]. J Clin Transl Hepatol, 2018, 6(1):25-34.
[13] CAO Z,LIU Y, MA L,et al.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4):1058-1066.
[14] WU FP, LU R, LIU YX,et al.Efficacy and safety of peginterferon alpha mono- therapy in Chinese inactive chronic hepatitis B virus carriers[J]. Liver Int, 2021, 41(9):2032-2045.
[15] DE NIET A, JANSEN L, STELMA F, et al.Pegylated interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial[J].Lancet Gastroenterol Hepatol, 2017,2(8):576-584.
[16] XU W, Li Q, HUANG C, et al.Efficacy of peginterferon-nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB[J]. Hepatol Int, 2021,15(1):51-59.
[17] ZENG QL, YU ZJ, SHANG J,et al. Short-term peginterferon-induced high functional cure rate in inactive chronic hepatitis B virus carriers with low surface antigen levels[J].Open Forum Infect Dis, 2020, 7(6):ofaa208.
[18] 易永祥. 乙型肝炎病毒的分子流行病学研究进展[J/CD]. 新发传染病电子杂志, 2020, 5(1):1-7.
[19] ZHENG JR,WANG ZL, FENG B.Hepatitis B functional cure and immune response[J]. Front Immunol, 2022,13: 1075916.
[20] RENTIYA ZS, WELLS M, BAE J, et al.Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations[J].Graefes Arch Clin Exp Ophthalmol, 2019, 257(3):447-452.